Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that patients with AA showed a high willingness to trade off lifespan for better disease-specific quality of life, indicating a significant disease burden.

This study found that alefacept showed no significant improvement in treating severe alopecia areata compared to placebo over a 24-week period.

This study found that Aire‒/‒ mice spontaneously developed persistent AA-like lesions, highlighting a potential role for AIRE in hair follicle biology and pathogenesis of alopecia areata.

Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.

This study found that multidisciplinary group medical visits for patients with alopecia areata improved patient satisfaction, knowledge, and access to care at Lahey Hospital and Medical Center.

This study observed that in a large, diverse US adult population, skin of color was associated with a higher prevalence of alopecia areata, whereas lower prevalence was seen among those with lower education, income, and lacking health insurance.

This article presents a dissenting opinion, arguing that the case described by Dr. Molina et al. was diffuse alopecia areata, not acute alopecia areata as claimed, emphasizing the importance of distinct clinical differences.

This study suggests that the rs2075876 variant in the AIRE gene may significantly increase susceptibility to alopecia areata in the examined male population.

In this case study, the researchers investigated a 44-year-old woman who developed rapidly progressing alopecia universalis after receiving a COVID-19 vaccine, and reviewed existing literature to explore potential links between COVID-19 vaccines and autoimmune hair loss conditions like alopecia areata and universalis.

This study found that phototoxic psoralen and ultraviolet A therapy with topical 8-MOP was effective in treating alopecia areata resistant to other treatments, improving hair regrowth with minimal side effects.

This study assessed the psychosocial impact and disease burden of alopecia areata among adolescents and adults in Australia, finding substantial impacts on physical, emotional, and quality of life overall, with greater disease burden in patients experiencing more extensive hair loss.

This study found that US adolescents with alopecia areata, especially those with alopecia totalis or universalis, experience significantly higher healthcare costs and resource use compared to matched controls.

This study reports that polyphenols from Annurca apples may safely promote hair growth and protect against chemotherapy-induced alopecia without interfering with chemotherapy regimens.

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

This study found that Black patients with alopecia areata showed an average 20% reduction in scalp involvement after JAK inhibitor therapy, indicating positive treatment outcomes in this group.

This genome-wide association study identified several genetic markers, including specific SNPs and HLA genotypes, associated with alopecia areata susceptibility in the Taiwanese population, highlighting key pathways involved in immune response and offering insights into the genetic origins of this autoimmune condition.

In this update, researchers incorporated TGA-approved Janus Kinase inhibitors into the Australian treatment guidelines for chronic, moderate to severe Alopecia areata, aiming to enhance recommended therapies by providing guidance on the use and management of these systemic medications.

This research presents the Dodatek A model, elaborating on androgen function through new mathematical indices and methodological improvements, shifting focus from serum hormone concentrations to system interactions to better describe androgen activity comprehensively.

This case report describes a woman with alopecia universalis, resistant to multiple treatments, who experienced successful hair regrowth with adalimumab, suggesting potential mechanisms for future investigation.

In a mouse model study, researchers found that mutations in Aire reduced alopecia areata frequency, while Notch4 mutations did not lead to the disease, likely due to proximity with a resistance gene.

In this case report, a 47-year-old male with Alopecia Universalis experienced complete hair regrowth after more than two years of homeopathic treatment under Dr. Batra’s care.

This study found that Egyptian patients with alopecia areata had a significant presence of sensorineural hearing loss compared to controls, correlated with the severity, duration, and recurrence of the disease.

This study found significant differences in enrollment and completion rates among racial and ethnic groups in alopecia areata clinical trials, with Black patients showing lower enrollment and higher dropout rates compared to other groups.

This study found that patients with alopecia areata have significantly higher medication adherence than those with atopic dermatitis, potentially due to the stability and controllability of alopecia areata symptoms.

This review discusses the economic burden of alopecia areata in adolescents and reports no new results; the authors note that evidence in this area is limited.

This study found that Annurca apple polyphenolic extracts reprogram hair follicle metabolism in mice, enhancing mitochondrial activity and keratin production while inhibiting some metabolic pathways.

In this randomized controlled trial, researchers found that participants with androgenic alopecia taking an Annurca apple extract supplement showed significant increases in hair density and weight and reduced hair loss compared to a placebo, with good skin and gastrointestinal tolerability over 180 days.

In this study, 1.9% of patients at a dermatology outpatient department were diagnosed with alopecia areata, with the most common affected age group being 20-40 years.

This analysis highlights the substantial financial burden AA creates in Saudi Arabia, emphasizing the importance of early diagnosis and standardized treatment protocols to improve resource allocation and patient outcomes.